Document detail
ID

oai:arXiv.org:2310.06696

Topic
Statistics - Methodology
Author
Wang, Runqiu Dai, Ran Huang, Ying Neuhouser, Marian L. Lampe, Johanna W. Raftery, Daniel Tabung, Fred K. Zheng, Cheng
Category

Statistics

Year

2023

listing date

10/14/2023

Keywords
associated metabolites disease cancer methodology data
Metrics

Abstract

The rapidly expanding field of metabolomics presents an invaluable resource for understanding the associations between metabolites and various diseases.

However, the high dimensionality, presence of missing values, and measurement errors associated with metabolomics data can present challenges in developing reliable and reproducible methodologies for disease association studies.

Therefore, there is a compelling need to develop robust statistical methods that can navigate these complexities to achieve reliable and reproducible disease association studies.

In this paper, we focus on developing such a methodology with an emphasis on controlling the False Discovery Rate during the screening of mutual metabolomic signals for multiple disease outcomes.

We illustrate the versatility and performance of this procedure in a variety of scenarios, dealing with missing data and measurement errors.

As a specific application of this novel methodology, we target two of the most prevalent cancers among US women: breast cancer and colorectal cancer.

By applying our method to the Wome's Health Initiative data, we successfully identify metabolites that are associated with either or both of these cancers, demonstrating the practical utility and potential of our method in identifying consistent risk factors and understanding shared mechanisms between diseases.

Wang, Runqiu,Dai, Ran,Huang, Ying,Neuhouser, Marian L.,Lampe, Johanna W.,Raftery, Daniel,Tabung, Fred K.,Zheng, Cheng, 2023, Variable selection with FDR control for noisy data -- an application to screening metabolites that are associated with breast and colorectal cancer

Document

Open

Share

Source

Articles recommended by ES/IODE AI

Batoclimab as induction and maintenance therapy in patients with myasthenia gravis: rationale and study design of a phase 3 clinical trial
gravis myasthenia study clinical phase baseline improvement mg-adl 340 week trial placebo period mg maintenance qw